Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance.
暂无分享,去创建一个
Soo Hyun Lee | Seonwoo Kim | S. Shin | C. Daley | Keehoon Lee | M. Hahn | W. Koh | T. Oh | K. Jeon | S. H. Lee | Byeong-Ho Jeong | Go-eun Choi | Choul-Jae Won | Ki-Nam Min | Mi-Young Hahn
[1] Young Kil Park,et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. , 2009, American journal of respiratory and critical care medicine.
[2] Robert Horsburgh,et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.
[3] Inability of L22 ribosomal protein alteration to increase macrolide MICs in the absence of efflux mechanism in Haemophilus influenzae HMC-S. , 2004, The Journal of antimicrobial chemotherapy.
[4] J. Gaillard,et al. Assessment of Clarithromycin Susceptibility in Strains Belonging to the Mycobacterium abscessus Group by erm(41) and rrl Sequencing , 2010, Antimicrobial Agents and Chemotherapy.
[5] C. Daley,et al. Pulmonary non-tuberculous mycobacterial infections. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[6] L. Danziger,et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers , 1997, Antimicrobial agents and chemotherapy.
[7] W. Jacobs,et al. Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. , 2002, Microbiology.
[8] T. Shim,et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. , 2011, Respiratory medicine.
[9] John D. Mitchell,et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] C. Vilchèze,et al. Characterization of Mycobacterium smegmatis Expressing the Mycobacterium tuberculosis Fatty Acid Synthase I (fas1) Gene , 2004, Journal of bacteriology.
[11] Thomas D. Schmittgen,et al. Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.
[12] O. Kwon,et al. Efficient Differentiation of Mycobacterium abscessus Complex Isolates to the Species Level by a Novel PCR-Based Variable-Number Tandem-Repeat Assay , 2010, Journal of Clinical Microbiology.
[13] Young Kil Park,et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. , 2011, American journal of respiratory and critical care medicine.
[14] R. Wallace,,et al. A Novel Gene, erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates of Mycobacterium abscessus but Is Absent from Mycobacterium chelonae , 2008, Antimicrobial Agents and Chemotherapy.
[15] B. Wanner,et al. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[16] C. Barry,et al. Comment on: Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. , 2012, The Journal of antimicrobial chemotherapy.
[17] K. Lee,et al. Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy. , 2012, Radiology.
[18] Gilbert Greub,et al. Amoebal Coculture of “Mycobacterium massiliense” sp. nov. from the Sputum of a Patient with Hemoptoic Pneumonia , 2004, Journal of Clinical Microbiology.
[19] H. Goossens,et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study , 2007, The Lancet.
[20] B. Gicquel,et al. Mycobacterium abscessus: a new antibiotic nightmare. , 2012, The Journal of antimicrobial chemotherapy.
[21] Po-Yu Liu,et al. Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing. , 2010, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[22] S. Shin,et al. Rapid and Reliable Method for Quantification of Mycobacterium paratuberculosis by Use of the BACTEC MGIT 960 System , 2007, Journal of Clinical Microbiology.
[23] A. Ishizaka,et al. Concentrations of clarithromycin and active metabolite in the epithelial lining fluid of patients with Mycobacterium avium complex pulmonary disease. , 2009, Pulmonary pharmacology & therapeutics.
[24] J. Zuckerman,et al. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). , 2011, The Medical clinics of North America.
[25] S. Chopra,et al. Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. , 2011, The Journal of antimicrobial chemotherapy.
[26] Y. Kook,et al. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns , 2010, Microbiology and immunology.
[27] S. Niemann,et al. Thr202Ala in thyA Is a Marker for the Latin American Mediterranean Lineage of the Mycobacterium tuberculosis Complex Rather than Para-Aminosalicylic Acid Resistance , 2010, Antimicrobial Agents and Chemotherapy.
[28] D. Griffith,et al. Therapy of refractory nontuberculous mycobacterial lung disease , 2012, Current opinion in infectious diseases.
[29] Didier Raoult,et al. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. , 2006, International journal of systematic and evolutionary microbiology.
[30] G. Scheffer,et al. Emergence and Persistence of Macrolide Resistance in Oropharyngeal Flora and Elimination of Nasal Carriage of Staphylococcus aureus after Therapy with Slow-Release Clarithromycin: a Randomized, Double-Blind, Placebo-Controlled Study , 2004, Antimicrobial Agents and Chemotherapy.
[31] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[32] D. Rubinsztein,et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. , 2011, The Journal of clinical investigation.
[33] D. Xuan,et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin , 1996, Antimicrobial agents and chemotherapy.
[34] R. Wallace,,et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes , 2011 .